Sunday, June 26, 2022
Cannabis News Daily
No Result
View All Result
  • Home
  • Cannabis News
  • Medical Marijuana
  • Legalization
  • Cannabis Business
  • Cannabis Laws
  • Cannabis Retail
No Result
View All Result
  • Home
  • Cannabis News
  • Medical Marijuana
  • Legalization
  • Cannabis Business
  • Cannabis Laws
  • Cannabis Retail
No Result
View All Result
Cannabis News Daily
No Result
View All Result
Home Cannabis News

Start-up focused on painkilling effects of cannabis to list in London

cannabisnews by cannabisnews
May 18, 2021
in Cannabis News
0
Start-up focused on painkilling effects of cannabis to list in London
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


Oxford Cannabinoid Technologies, a biotech company developing medicines that mimic the painkilling effects of cannabis, is to float on the main London market later this week.

OCT, which started up four years ago with a venture-capital funded programme of research into medical marijuana at Oxford university, will raise £16.5m from the initial public offering, which is heavily oversubscribed. Its valuation after the listing is expected to be about £51.5m.

Neil Mahapatra, OCT co-founder and executive chair, said the decision to list in London followed last autumn’s statement by the Financial Conduct Authority that medicinal cannabis companies were welcome to list in London, as well as investors’ enthusiasm for biotech more broadly.

“We were thinking about a private funding round but market conditions appear buoyant for our type of company,” he said.

A role model for OCT is GW Pharmaceuticals, the UK-based pioneer of converting knowledge of cannabis biochemistry into licensed medicines, says Mahapatra. GW reported selling more than $500m of its cannabis-derived treatment for childhood epilepsy, Epidiolex, last year, and Jazz Pharmaceuticals agreed to buy the Nasdaq-listed company in February for $7.2bn. 

OCT co-founder and executive chairman Neil Mahapatra, left, with other senior team members
OCT co-founder and executive chair Neil Mahapatra, left, with chief executive John Lucas, second left, and other senior team members © Andrew Lunn

But a key difference between the two companies is that GW manufactures drugs from cannabis plants while OCT will make compounds that resemble natural cannabinoids synthetically in chemical reactors, said John Lucas, OCT chief executive.

Proceeds of the IPO will be used to prepare its two most advanced drug candidates to begin clinical trials in the third quarter of 2022. One originated from OCT’s own research while the other was licensed in from AskAt, a Japanese spinout from Pfizer. Two more compounds are expected to start clinical testing in 2023 and 2024.

Kingsley Capital, a London private equity and venture capital business, set up OCT in 2017 to fund research at Oxford investigating several pharmaceutical uses of cannabinoids. The results showed that the most promising avenue for the company would be neuropathic pain, caused by nerve damage or disease, which represents a world market worth £7bn a year according to OCT.

However, the company was not really an Oxford university spinout, Mahapatra said, because OCT was paying for research there on a “fee for service” basis, which leaves all intellectual property with the company. Two projects are at present in progress at the university, both investigating the role of cannabinoids in pain, but Oxford has no financial stake in OCT.

In the existing shareholding structure, wealthy individuals own 47.8 per cent of the company. Kingsley Capital owns 32.2 per cent and Imperial Brands, the tobacco group, has 16.9 per cent. The remaining 3.2 per cent is in the hands of Casa Verde, a specialist cannabis investment firm.

More companies in the medicinal marijuana sector have made moves to list in the UK since the FCA issued its guidelines. Both Tel Aviv-based Kanabo, which is developing a means to distribute cannabis-derived products for medical patients through vaporisers, and MGC Pharmaceuticals, which sells THC tinctures and is developing a cannabis-based epilepsy drug, floated in London in February.



Source link

RELATED POSTS

Cannabis Control Division spokeswoman paid $125 an hour under no-bid contract | Local News

Referendum to stop Red Bluff Cannabis Ordinance fails, city to proceed as planned – KRCR

ShareTweetPin
cannabisnews

cannabisnews

Related Posts

Cannabis Control Division spokeswoman paid $125 an hour under no-bid contract | Local News

Cannabis Control Division spokeswoman paid $125 an hour under no-bid contract | Local News

by cannabisnews
March 26, 2022
0

Generating positive press about New Mexico’s burgeoning recreational cannabis industry is a high-dollar endeavor.The state’s new Cannabis Control Division...

Referendum to stop Red Bluff Cannabis Ordinance fails, city to proceed as planned – KRCR

Referendum to stop Red Bluff Cannabis Ordinance fails, city to proceed as planned – KRCR

by cannabisnews
March 26, 2022
0

Referendum to stop Red Bluff Cannabis Ordinance fails, city to proceed as planned  KRCR Source link

Warily, tribes prepare for cannabis ventures in New Mexico

Warily, tribes prepare for cannabis ventures in New Mexico

by cannabisnews
March 26, 2022
0

By MORGAN LEEAssociated Press SANTA FE, N.M. (AP) — Two tribal communities are ensuring they’ll be free from federal...

Ready or Not, New Mexico Adult-Use Sales Coming

Ready or Not, New Mexico Adult-Use Sales Coming

by cannabisnews
March 25, 2022
0

New Mexico will become the 13th state to launch commercial adult-use cannabis sales in the U.S. with an April...

Meet Rosie: The robot ensuring adequate cannabis supply as recreational sales start April 1

Meet Rosie: The robot ensuring adequate cannabis supply as recreational sales start April 1

by cannabisnews
March 25, 2022
0

"The biggest thing in cannabis is just making sure you have enough supply both to meet the demand of...

Next Post
Drug Arrests, Johnson Vs Whitmer, Mask Mandate, Medical Marijuana

Drug Arrests, Johnson Vs Whitmer, Mask Mandate, Medical Marijuana

Middletown pauses on banning pot businesses

Middletown pauses on banning pot businesses

RECOMMENDED

Valley News – Column: Small producers deserve direct access to market

Valley News – Column: Small producers deserve direct access to market

March 26, 2022

Decriminalization: The pathway to legalization and cannabis equity | Nikki Fried – South Florida Sun Sentinel

March 26, 2022
  • 22M Fans
  • 114 Followers
  • 650 Followers
  • 23.6k Followers

MOST VIEWED

  • US Hemp and Cannabis Industry Leaders to Participate with Government at Event Celebrating New Legalization In Costa Rica

    US Hemp and Cannabis Industry Leaders to Participate with Government at Event Celebrating New Legalization In Costa Rica

    0 shares
    Share 0 Tweet 0
  • Oklahoma Cannabis Pioneer Joins Forces with Budding Cannabis Brand Ganja Goat Guru

    1 shares
    Share 0 Tweet 0
  • New Jersey Begins Accepting Recreational Cannabis License Applications: When Will Dispensaries Open?

    0 shares
    Share 0 Tweet 0
  • Federal Marijuana Legalization Bill May Receive House Floor Vote Next Week, Sources Say

    0 shares
    Share 0 Tweet 0
  • Legalizing recreational marijuana in Florida

    0 shares
    Share 0 Tweet 0

Recent News

Valley News – Column: Small producers deserve direct access to market

Valley News – Column: Small producers deserve direct access to market

March 26, 2022

Decriminalization: The pathway to legalization and cannabis equity | Nikki Fried – South Florida Sun Sentinel

March 26, 2022
Will SAFE Banking Act help?

Will SAFE Banking Act help?

March 26, 2022

CATEGORY

  • Cannabis Business
  • Cannabis Laws
  • Cannabis News
  • Cannabis Retail
  • Legalization
  • Medical Marijuana

Contact Us

  • Privacy & Policy
  • About Us
  • Contact Us

© 2021 Copyright Cannabis News Daily

No Result
View All Result
  • Home
  • Cannabis News
  • Medical Marijuana
  • Legalization
  • Cannabis Business
  • Cannabis Laws
  • Cannabis Retail

© 2021 Copyright Cannabis News Daily